董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Taylor Harris | 男 | Director | 44 | 未披露 | 3.50 | 2021-01-28 |
| Christopher Gaulin | 男 | Chief Executive Officer and Director | 45 | 未披露 | 未持股 | 2021-01-28 |
| Joseph Healey | 男 | Director, Chairman | 54 | 未披露 | 495.50 | 2021-01-28 |
| Avi Horev | 男 | Director | 46 | 未披露 | 未持股 | 2021-01-28 |
| Kenan Turnacioglu | 男 | Director | 50 | 未披露 | 未持股 | 2021-01-28 |
| Michael Weinstein | 男 | Director | 50 | 未披露 | 3.50 | 2021-01-28 |
| Christopher Wolfgang | 男 | Director | 54 | 未披露 | 3.50 | 2021-01-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Christopher Gaulin | 男 | Chief Executive Officer and Director | 45 | 未披露 | 未持股 | 2021-01-28 |
| Christine Clarke | 女 | Chief Financial Officer | 42 | 未披露 | 未持股 | 2021-01-28 |
| George Petrocheilos | 男 | President | 29 | 未披露 | 未持股 | 2021-01-28 |
董事简历
中英对照 | 中文 | 英文- Taylor Harris
-
Taylor Harris，自2020年12月起担任董事会成员。Harris先生自2018年4月起担任MyoKardia，Inc.的首席财务官，该公司是一家临床阶段的生物制药公司，直至该公司于2020年11月被百时美施贵宝收购。在此之前，Harris先生曾于2016年3月在ZELTIQ Aesthetics, Inc.担任高级副总裁兼首席财务官，该公司是一家营销和许可用于冷冻溶脂程序的设备的公司，直到该公司于2017年4月被Allergan plc.收购。Harris先生自2021年1月起担任HealthCor Catalio Acquisition Company的董事会成员，同时也是该公司审计委员会的成员。Harris先生拥有北卡罗来纳大学教堂山分校的物理学和经济学学士学位。
Taylor Harris has served as a member of board of directors since December 2020. Mr. Harris served as the Chief Financial Officer for MyoKardia, Inc., a clinical-stage biopharmaceutical company, from April 2018 until that company's acquisition by Bristol Myers Squibb in November 2020. Previously, Mr. Harris served as Senior Vice President and Chief Financial Officer of Zeltiq Aesthetics, Inc., a company that markets and licenses devices used for cryolipolysis procedures, from March 2016 until that company's acquisition by Allergan plc. in April 2017. Mr. Harris has served as a member of the board of directors of HealthCor Catalio Acquisition Company, where he is also a member of the audit committee, since January 2021. Mr. Harris holds a B.A. in Physics and Economics from the University of North Carolina at Chapel Hill. - Taylor Harris，自2020年12月起担任董事会成员。Harris先生自2018年4月起担任MyoKardia，Inc.的首席财务官，该公司是一家临床阶段的生物制药公司，直至该公司于2020年11月被百时美施贵宝收购。在此之前，Harris先生曾于2016年3月在ZELTIQ Aesthetics, Inc.担任高级副总裁兼首席财务官，该公司是一家营销和许可用于冷冻溶脂程序的设备的公司，直到该公司于2017年4月被Allergan plc.收购。Harris先生自2021年1月起担任HealthCor Catalio Acquisition Company的董事会成员，同时也是该公司审计委员会的成员。Harris先生拥有北卡罗来纳大学教堂山分校的物理学和经济学学士学位。
- Taylor Harris has served as a member of board of directors since December 2020. Mr. Harris served as the Chief Financial Officer for MyoKardia, Inc., a clinical-stage biopharmaceutical company, from April 2018 until that company's acquisition by Bristol Myers Squibb in November 2020. Previously, Mr. Harris served as Senior Vice President and Chief Financial Officer of Zeltiq Aesthetics, Inc., a company that markets and licenses devices used for cryolipolysis procedures, from March 2016 until that company's acquisition by Allergan plc. in April 2017. Mr. Harris has served as a member of the board of directors of HealthCor Catalio Acquisition Company, where he is also a member of the audit committee, since January 2021. Mr. Harris holds a B.A. in Physics and Economics from the University of North Carolina at Chapel Hill.
- Christopher Gaulin
-
Christopher Gaulin担任我们的首席执行官，也是我们董事会的成员。Gaulin先生是Healthcor的投资组合经理。高林于2018年从索罗斯基金管理公司（Soros Fund Management）加盟Healthcor，管理该公司的梦百合股权投资。在索罗斯之前，高林曾在Maverick Capital工作了14年，最近的职位是梦百合部门主管。作为梦百合部门主管，高林负责管理该公司数十亿美元的梦百合股票投资组合，并担任Maverick的股票委员会和咨询委员会成员。在领导Maverick的梦百合团队之前，高林曾管理该公司的小型股投资组合三年。Gaulin先生于2003年加入Maverick，担任涵盖消费者和商业服务部门的高级分析师。在Maverick之前，Gaulin先生是JP Morgan的高级分析师。Gaulin先生于1997年毕业于波士顿学院（Boston College）金融学B.S.。
Christopher Gaulin serves as our Chief Executive Officer and is a member of our board of directors. Mr. Gaulin is a Portfolio Manager at HealthCor. Mr. Gaulin joined HealthCor in 2018 from Soros Fund Management where he managed the firm’s healthcare equity investments. Prior to Soros, Mr. Gaulin spent 14 years at Maverick Capital, most recently as Healthcare Sector Head. As Healthcare Sector Head, Mr. Gaulin was responsible for managing the firm’s multi-billion healthcare equity portfolio and served as a member of Maverick’s Stock Committee and Advisory Committee. Prior to leading the healthcare team at Maverick, Mr. Gaulin ran the firm’s small cap portfolio for three years. Mr. Gaulin joined Maverick in 2003 as a Senior Analyst covering the consumer and business services sectors. Prior to Maverick, Mr. Gaulin was a Senior Analyst at JP Morgan. Mr. Gaulin graduated with a B.S. in Finance from Boston College in 1997. - Christopher Gaulin担任我们的首席执行官，也是我们董事会的成员。Gaulin先生是Healthcor的投资组合经理。高林于2018年从索罗斯基金管理公司（Soros Fund Management）加盟Healthcor，管理该公司的梦百合股权投资。在索罗斯之前，高林曾在Maverick Capital工作了14年，最近的职位是梦百合部门主管。作为梦百合部门主管，高林负责管理该公司数十亿美元的梦百合股票投资组合，并担任Maverick的股票委员会和咨询委员会成员。在领导Maverick的梦百合团队之前，高林曾管理该公司的小型股投资组合三年。Gaulin先生于2003年加入Maverick，担任涵盖消费者和商业服务部门的高级分析师。在Maverick之前，Gaulin先生是JP Morgan的高级分析师。Gaulin先生于1997年毕业于波士顿学院（Boston College）金融学B.S.。
- Christopher Gaulin serves as our Chief Executive Officer and is a member of our board of directors. Mr. Gaulin is a Portfolio Manager at HealthCor. Mr. Gaulin joined HealthCor in 2018 from Soros Fund Management where he managed the firm’s healthcare equity investments. Prior to Soros, Mr. Gaulin spent 14 years at Maverick Capital, most recently as Healthcare Sector Head. As Healthcare Sector Head, Mr. Gaulin was responsible for managing the firm’s multi-billion healthcare equity portfolio and served as a member of Maverick’s Stock Committee and Advisory Committee. Prior to leading the healthcare team at Maverick, Mr. Gaulin ran the firm’s small cap portfolio for three years. Mr. Gaulin joined Maverick in 2003 as a Senior Analyst covering the consumer and business services sectors. Prior to Maverick, Mr. Gaulin was a Senior Analyst at JP Morgan. Mr. Gaulin graduated with a B.S. in Finance from Boston College in 1997.
- Joseph Healey
-
Joseph Healey是我们的董事会主席。Healey先生是Healthcor的联合创始人和投资组合经理。加入Healthcor之前，Healey从2000年1月到2005年3月担任SAC投资组合经理。任职SAC公司之前，他曾担任Kingdon Capital Management公司的医疗保健投资组合经理（从1997年到2000年），以及Dreyfus Corporation的分析师兼投资组合经理（从1992年到1997年）。Healey先生从1988年到1992年还担任Walter Reed Army Medical Center美国陆军医疗服务公司（U.S.Army Medical Service Corp）的中尉。Healey先生于1988年毕业于波士顿大学（Boston University），获得生物医学工程学士学位，并于1993年获得马里兰大学（University of Maryland）技术管理硕士学位。Healey先生于1996年成为特许金融分析师CFA。
Joseph Healey is the chairman of our board of directors. Mr. Healey is a Co-Founder and Portfolio Manager of HealthCor. Prior to HealthCor, Mr. Healey was a Portfolio Manager at SAC from January 2000 through March 2005. Prior to SAC, from 1997 to 2000 Mr. Healey was a health care Portfolio Manager at Kingdon Capital Management, and from 1992 until 1997 he was an Analyst and Portfolio Manager at Dreyfus Corporation. Mr. Healey also served as a First Lieutenant in the U.S. Army Medical Service Corp at the Walter Reed Army Medical Center from 1988 to 1992. Mr. Healey graduated from Boston University in 1988 with a B.A. in Biomedical Engineering and received his M.S. in Technology Management from the University of Maryland in 1993. Mr. Healey became a Chartered Financial Analyst CFA in 1996. - Joseph Healey是我们的董事会主席。Healey先生是Healthcor的联合创始人和投资组合经理。加入Healthcor之前，Healey从2000年1月到2005年3月担任SAC投资组合经理。任职SAC公司之前，他曾担任Kingdon Capital Management公司的医疗保健投资组合经理（从1997年到2000年），以及Dreyfus Corporation的分析师兼投资组合经理（从1992年到1997年）。Healey先生从1988年到1992年还担任Walter Reed Army Medical Center美国陆军医疗服务公司（U.S.Army Medical Service Corp）的中尉。Healey先生于1988年毕业于波士顿大学（Boston University），获得生物医学工程学士学位，并于1993年获得马里兰大学（University of Maryland）技术管理硕士学位。Healey先生于1996年成为特许金融分析师CFA。
- Joseph Healey is the chairman of our board of directors. Mr. Healey is a Co-Founder and Portfolio Manager of HealthCor. Prior to HealthCor, Mr. Healey was a Portfolio Manager at SAC from January 2000 through March 2005. Prior to SAC, from 1997 to 2000 Mr. Healey was a health care Portfolio Manager at Kingdon Capital Management, and from 1992 until 1997 he was an Analyst and Portfolio Manager at Dreyfus Corporation. Mr. Healey also served as a First Lieutenant in the U.S. Army Medical Service Corp at the Walter Reed Army Medical Center from 1988 to 1992. Mr. Healey graduated from Boston University in 1988 with a B.A. in Biomedical Engineering and received his M.S. in Technology Management from the University of Maryland in 1993. Mr. Healey became a Chartered Financial Analyst CFA in 1996.
- Avi Horev
-
Avi Horev是Healthcor的高级合伙人和投资组合经理。Horev先生于2005年Healthcor推出时加入Healthcor。Horev从2003年到2005年在Art Cohen and Healey&8217；s Team担任SAC医疗设备研究分析师。在SAC工作之前，Horev先生从1997年到2003年是JP Morgan的医疗保健股票研究分析师。Horev先生于1997年毕业于利哈伊大学（Lehigh University）金融学学士学位。
Avi Horev is a Senior Partner and Portfolio Manager of HealthCor. Mr. Horev joined HealthCor at the time of its launch in 2005. From 2003 to 2005 Mr. Horev worked with Art Cohen and Mr. Healey’s team as a medical device research analyst at SAC. Prior to working at SAC, Mr. Horev was a health care equity research analyst at JP Morgan from 1997 to 2003. Mr. Horev graduated with a B.S. in Finance from Lehigh University in 1997. - Avi Horev是Healthcor的高级合伙人和投资组合经理。Horev先生于2005年Healthcor推出时加入Healthcor。Horev从2003年到2005年在Art Cohen and Healey&8217；s Team担任SAC医疗设备研究分析师。在SAC工作之前，Horev先生从1997年到2003年是JP Morgan的医疗保健股票研究分析师。Horev先生于1997年毕业于利哈伊大学（Lehigh University）金融学学士学位。
- Avi Horev is a Senior Partner and Portfolio Manager of HealthCor. Mr. Horev joined HealthCor at the time of its launch in 2005. From 2003 to 2005 Mr. Horev worked with Art Cohen and Mr. Healey’s team as a medical device research analyst at SAC. Prior to working at SAC, Mr. Horev was a health care equity research analyst at JP Morgan from 1997 to 2003. Mr. Horev graduated with a B.S. in Finance from Lehigh University in 1997.
- Kenan Turnacioglu
-
Kenan Turnacioglu，是Catalio公司的普通合伙人，在那里他也任职于投资委员会。Turnacioglu博士还是从Memorial Sloan Kettering分拆出来的机器学习病理公司PaigeAI的董事长。Turnacioglu博士于2011年共同创立了PointState Capital，LP，管理梦百合和消费领域的投资组合和投资团队，并于2018年离职。从2001年到2010年，Turnacioglu博士在Duquesne Capital Management，LLC工作，管理梦百合投资。在担任这些职位时，Turnacioglu博士还于2013年至2016年在StemcentRx Agensys和NYU Langone Cancer Center的董事会任职。从1998年到2000年，Turnacioglu博士在瑞士信贷（Credit Suisse）担任生物技术团队的分析师。Turnacioglu博士在罗格斯大学（Rutgers University）获得学士学位，在宾夕法尼亚大学（University of Pennsylvania）获得博士学位，之后成为约翰霍普金斯大学（Johns Hopkins University）的博士后。
Kenan Turnacioglu is a General Partner at Catalio, where he also serves on the Investment Committee. Dr. Turnacioglu is also the Chairman of PaigeAI, a machine learning pathology company spun out of Memorial Sloan Kettering. In 2011 Dr. Turnacioglu co-founded PointState Capital, LP and managed the portfolios and investment teams in Healthcare and Consumer sectors, before departing in 2018. From 2001 to 2010 Dr. Turnacioglu worked at Duquesne Capital Management, LLC managing healthcare investments. While at these positions, Dr. Turnacioglu also served on the boards of StemCentrx from 2013 to 2016 Agensys from 2004 to 2007 and NYU Langone Cancer Center from 2010 to 2015. From 1998 to 2000 Dr. Turnacioglu worked at Credit Suisse as an analyst on the biotech team. Dr. Turnacioglu earned a B.A. from Rutgers University, and a Ph.D from the University of Pennsylvania, before becoming a Post-Doctoral Fellow at Johns Hopkins University. - Kenan Turnacioglu，是Catalio公司的普通合伙人，在那里他也任职于投资委员会。Turnacioglu博士还是从Memorial Sloan Kettering分拆出来的机器学习病理公司PaigeAI的董事长。Turnacioglu博士于2011年共同创立了PointState Capital，LP，管理梦百合和消费领域的投资组合和投资团队，并于2018年离职。从2001年到2010年，Turnacioglu博士在Duquesne Capital Management，LLC工作，管理梦百合投资。在担任这些职位时，Turnacioglu博士还于2013年至2016年在StemcentRx Agensys和NYU Langone Cancer Center的董事会任职。从1998年到2000年，Turnacioglu博士在瑞士信贷（Credit Suisse）担任生物技术团队的分析师。Turnacioglu博士在罗格斯大学（Rutgers University）获得学士学位，在宾夕法尼亚大学（University of Pennsylvania）获得博士学位，之后成为约翰霍普金斯大学（Johns Hopkins University）的博士后。
- Kenan Turnacioglu is a General Partner at Catalio, where he also serves on the Investment Committee. Dr. Turnacioglu is also the Chairman of PaigeAI, a machine learning pathology company spun out of Memorial Sloan Kettering. In 2011 Dr. Turnacioglu co-founded PointState Capital, LP and managed the portfolios and investment teams in Healthcare and Consumer sectors, before departing in 2018. From 2001 to 2010 Dr. Turnacioglu worked at Duquesne Capital Management, LLC managing healthcare investments. While at these positions, Dr. Turnacioglu also served on the boards of StemCentrx from 2013 to 2016 Agensys from 2004 to 2007 and NYU Langone Cancer Center from 2010 to 2015. From 1998 to 2000 Dr. Turnacioglu worked at Credit Suisse as an analyst on the biotech team. Dr. Turnacioglu earned a B.A. from Rutgers University, and a Ph.D from the University of Pennsylvania, before becoming a Post-Doctoral Fellow at Johns Hopkins University.
- Michael Weinstein
-
Michael Weinstein是高级副总裁，战略，也是世界领先的医疗技术公司美敦力公司（Medtronic plc）的执行委员会成员。在该职位上，Weinstein先生监管美敦力公司的全球战略，包括为业务发展，资本部署以及美敦力公司业务的整体战略方向提供建议和投入。在加入美敦力之前，韦恩斯坦曾在摩根大通公司（J.P.Morgan&Co.）工作了25年，担任董事总经理期间，他曾领导该公司的股票研究梦百合部门。Weinstein先生于1992年加入摩根大通（J.P.Morgan），并于1995年至2018年担任公司高级医疗技术分析师。Weinstein先生在机构投资者和Greenwich Associates的年度调查中都是14次排名第一的分析师。2013年他被提名为机构投资者名人堂。Weinstein先生在乔治敦大学（Georgetown University）获得国际管理学士学位。
Michael Weinstein is Senior Vice President, Strategy and a member of the Executive Committee at Medtronic PLC, one of the world’s leading medical technology companies. In this role, Mr. Weinstein oversees global strategy for Medtronic, including providing counsel and input on business development, capital deployment, and the overall strategic direction of Medtronic’s businesses. Prior to joining Medtronic, Mr. Weinstein spent 25 years at J.P. Morgan & Co., where as a Managing Director he led the firm’s Healthcare group within Equity Research. Mr. Weinstein joined J.P. Morgan in 1992 and was the firm’s senior medical technology analyst from 1995 to 2018. Mr. Weinstein is a 14-time #1 ranked analyst in the annual surveys of both Institutional Investor and Greenwich Associates. In 2013 he was named to the Institutional Investor Hall of Fame. Mr. Weinstein received his bachelor’s degree in International Management from Georgetown University. - Michael Weinstein是高级副总裁，战略，也是世界领先的医疗技术公司美敦力公司（Medtronic plc）的执行委员会成员。在该职位上，Weinstein先生监管美敦力公司的全球战略，包括为业务发展，资本部署以及美敦力公司业务的整体战略方向提供建议和投入。在加入美敦力之前，韦恩斯坦曾在摩根大通公司（J.P.Morgan&Co.）工作了25年，担任董事总经理期间，他曾领导该公司的股票研究梦百合部门。Weinstein先生于1992年加入摩根大通（J.P.Morgan），并于1995年至2018年担任公司高级医疗技术分析师。Weinstein先生在机构投资者和Greenwich Associates的年度调查中都是14次排名第一的分析师。2013年他被提名为机构投资者名人堂。Weinstein先生在乔治敦大学（Georgetown University）获得国际管理学士学位。
- Michael Weinstein is Senior Vice President, Strategy and a member of the Executive Committee at Medtronic PLC, one of the world’s leading medical technology companies. In this role, Mr. Weinstein oversees global strategy for Medtronic, including providing counsel and input on business development, capital deployment, and the overall strategic direction of Medtronic’s businesses. Prior to joining Medtronic, Mr. Weinstein spent 25 years at J.P. Morgan & Co., where as a Managing Director he led the firm’s Healthcare group within Equity Research. Mr. Weinstein joined J.P. Morgan in 1992 and was the firm’s senior medical technology analyst from 1995 to 2018. Mr. Weinstein is a 14-time #1 ranked analyst in the annual surveys of both Institutional Investor and Greenwich Associates. In 2013 he was named to the Institutional Investor Hall of Fame. Mr. Weinstein received his bachelor’s degree in International Management from Georgetown University.
- Christopher Wolfgang
-
克里斯托弗·沃尔夫冈（Christopher Wolfgang）是约翰·L·卡梅伦（John L.Cameron）外科教授，也是约翰·霍普金斯医学公司（Johns Hopkins Medicine）胰腺外科主任。Wolfgang博士拥有额外的任命，包括Johns Hopkins医学院的病理学和肿瘤学教授。Wolfgang博士被选入Miller-Coulson Academy of Clinical Excellence和the Johns Hopkins School of Medicine杰出教学协会。Wolfgang博士被公认为胰腺癌临床护理和基础研究领域的世界领先专家和思想领袖之一。Wolfgang博士是全球最有经验的胰腺外科医生之一，亲自执行了1200多例Whipple手术。Wolfgang博士被认为是胰腺癌血管受累的首选外科医生之一，并领导他的团队推动血管重建作为胰腺癌切除的一部分，并切除转移到肝脏的胰腺癌。除了他的临床活动，Wolfgang博士还经营着一个研究项目，专注于了解转移性扩散——肿瘤切除后治疗失败的最重要原因。Wolfgang博士发表了400多篇同行评议的研究文章，Google Scholar H-Index为97，引用次数超过4万次。Wolfgang博士于1998年毕业于天普大学医学院（Temple University School of Medicine），获得医学博士和博士学位生物化学联合学位。2020年1月，Wolfgang博士担任纽约曼哈顿NYU Langone胰腺外科主任。
Christopher Wolfgang is the John L. Cameron Professor of Surgery and the Chief of Pancreatic Surgery at Johns Hopkins Medicine. Dr. Wolfgang holds additional appointments including a Professor of Pathology and Oncology at the Johns Hopkins School of Medicine. Dr. Wolfgang was elected into both the Miller-Coulson Academy of Clinical Excellence and the Distinguished Teaching Society of the Johns Hopkins School of Medicine. Dr. Wolfgang is recognized as one of the world’s leading experts and thought leaders in pancreatic cancer clinical care and basic research. Dr. Wolfgang is one of the most experienced pancreatic surgeons world-wide, personally having performed over 1200 Whipple operations. Dr. Wolfgang is considered one of the go-to surgeons for pancreatic cancer with vascular involvement and has led his group in pushing the envelope for vascular reconstruction as part of pancreatic cancer resection and in resecting pancreatic cancer metastatic to the liver. In addition to his clinical activity, Dr. Wolfgang runs a research program focused on the understanding of metastatic spread - the most important reason for treatment failure following tumor removal. Dr. Wolfgang has published over 400 peer-reviewed research articles and has a Google Scholar H-index of 97 with over 40000 citations of his work. Dr. Wolfgang graduated from Temple University School of Medicine in 1998 with a combined MD and PhD degree biochemistry. In January 2020 Dr. Wolfgang assumed the role of Chief of Pancreatic Surgery at NYU Langone in Manhattan, New York. - 克里斯托弗·沃尔夫冈（Christopher Wolfgang）是约翰·L·卡梅伦（John L.Cameron）外科教授，也是约翰·霍普金斯医学公司（Johns Hopkins Medicine）胰腺外科主任。Wolfgang博士拥有额外的任命，包括Johns Hopkins医学院的病理学和肿瘤学教授。Wolfgang博士被选入Miller-Coulson Academy of Clinical Excellence和the Johns Hopkins School of Medicine杰出教学协会。Wolfgang博士被公认为胰腺癌临床护理和基础研究领域的世界领先专家和思想领袖之一。Wolfgang博士是全球最有经验的胰腺外科医生之一，亲自执行了1200多例Whipple手术。Wolfgang博士被认为是胰腺癌血管受累的首选外科医生之一，并领导他的团队推动血管重建作为胰腺癌切除的一部分，并切除转移到肝脏的胰腺癌。除了他的临床活动，Wolfgang博士还经营着一个研究项目，专注于了解转移性扩散——肿瘤切除后治疗失败的最重要原因。Wolfgang博士发表了400多篇同行评议的研究文章，Google Scholar H-Index为97，引用次数超过4万次。Wolfgang博士于1998年毕业于天普大学医学院（Temple University School of Medicine），获得医学博士和博士学位生物化学联合学位。2020年1月，Wolfgang博士担任纽约曼哈顿NYU Langone胰腺外科主任。
- Christopher Wolfgang is the John L. Cameron Professor of Surgery and the Chief of Pancreatic Surgery at Johns Hopkins Medicine. Dr. Wolfgang holds additional appointments including a Professor of Pathology and Oncology at the Johns Hopkins School of Medicine. Dr. Wolfgang was elected into both the Miller-Coulson Academy of Clinical Excellence and the Distinguished Teaching Society of the Johns Hopkins School of Medicine. Dr. Wolfgang is recognized as one of the world’s leading experts and thought leaders in pancreatic cancer clinical care and basic research. Dr. Wolfgang is one of the most experienced pancreatic surgeons world-wide, personally having performed over 1200 Whipple operations. Dr. Wolfgang is considered one of the go-to surgeons for pancreatic cancer with vascular involvement and has led his group in pushing the envelope for vascular reconstruction as part of pancreatic cancer resection and in resecting pancreatic cancer metastatic to the liver. In addition to his clinical activity, Dr. Wolfgang runs a research program focused on the understanding of metastatic spread - the most important reason for treatment failure following tumor removal. Dr. Wolfgang has published over 400 peer-reviewed research articles and has a Google Scholar H-index of 97 with over 40000 citations of his work. Dr. Wolfgang graduated from Temple University School of Medicine in 1998 with a combined MD and PhD degree biochemistry. In January 2020 Dr. Wolfgang assumed the role of Chief of Pancreatic Surgery at NYU Langone in Manhattan, New York.
高管简历
中英对照 | 中文 | 英文- Christopher Gaulin
Christopher Gaulin担任我们的首席执行官，也是我们董事会的成员。Gaulin先生是Healthcor的投资组合经理。高林于2018年从索罗斯基金管理公司（Soros Fund Management）加盟Healthcor，管理该公司的梦百合股权投资。在索罗斯之前，高林曾在Maverick Capital工作了14年，最近的职位是梦百合部门主管。作为梦百合部门主管，高林负责管理该公司数十亿美元的梦百合股票投资组合，并担任Maverick的股票委员会和咨询委员会成员。在领导Maverick的梦百合团队之前，高林曾管理该公司的小型股投资组合三年。Gaulin先生于2003年加入Maverick，担任涵盖消费者和商业服务部门的高级分析师。在Maverick之前，Gaulin先生是JP Morgan的高级分析师。Gaulin先生于1997年毕业于波士顿学院（Boston College）金融学B.S.。
Christopher Gaulin serves as our Chief Executive Officer and is a member of our board of directors. Mr. Gaulin is a Portfolio Manager at HealthCor. Mr. Gaulin joined HealthCor in 2018 from Soros Fund Management where he managed the firm’s healthcare equity investments. Prior to Soros, Mr. Gaulin spent 14 years at Maverick Capital, most recently as Healthcare Sector Head. As Healthcare Sector Head, Mr. Gaulin was responsible for managing the firm’s multi-billion healthcare equity portfolio and served as a member of Maverick’s Stock Committee and Advisory Committee. Prior to leading the healthcare team at Maverick, Mr. Gaulin ran the firm’s small cap portfolio for three years. Mr. Gaulin joined Maverick in 2003 as a Senior Analyst covering the consumer and business services sectors. Prior to Maverick, Mr. Gaulin was a Senior Analyst at JP Morgan. Mr. Gaulin graduated with a B.S. in Finance from Boston College in 1997.- Christopher Gaulin担任我们的首席执行官，也是我们董事会的成员。Gaulin先生是Healthcor的投资组合经理。高林于2018年从索罗斯基金管理公司（Soros Fund Management）加盟Healthcor，管理该公司的梦百合股权投资。在索罗斯之前，高林曾在Maverick Capital工作了14年，最近的职位是梦百合部门主管。作为梦百合部门主管，高林负责管理该公司数十亿美元的梦百合股票投资组合，并担任Maverick的股票委员会和咨询委员会成员。在领导Maverick的梦百合团队之前，高林曾管理该公司的小型股投资组合三年。Gaulin先生于2003年加入Maverick，担任涵盖消费者和商业服务部门的高级分析师。在Maverick之前，Gaulin先生是JP Morgan的高级分析师。Gaulin先生于1997年毕业于波士顿学院（Boston College）金融学B.S.。
- Christopher Gaulin serves as our Chief Executive Officer and is a member of our board of directors. Mr. Gaulin is a Portfolio Manager at HealthCor. Mr. Gaulin joined HealthCor in 2018 from Soros Fund Management where he managed the firm’s healthcare equity investments. Prior to Soros, Mr. Gaulin spent 14 years at Maverick Capital, most recently as Healthcare Sector Head. As Healthcare Sector Head, Mr. Gaulin was responsible for managing the firm’s multi-billion healthcare equity portfolio and served as a member of Maverick’s Stock Committee and Advisory Committee. Prior to leading the healthcare team at Maverick, Mr. Gaulin ran the firm’s small cap portfolio for three years. Mr. Gaulin joined Maverick in 2003 as a Senior Analyst covering the consumer and business services sectors. Prior to Maverick, Mr. Gaulin was a Senior Analyst at JP Morgan. Mr. Gaulin graduated with a B.S. in Finance from Boston College in 1997.
- Christine Clarke
Christine Clarke是我们的首席财务官。Clarke女士于2006年加入Healthcor，自2007年起担任首席财务官。Clarke女士的职责包括会计，运营和人力资源，她在执行，评估，合规，费用，最佳执行和风险委员会任职。在加入Healthcor之前，Clarke女士从2004年到2006年担任Narragansett Management，L.P.的财务总监。从2000年到2004年，她曾担任普华永道会计师事务所（PricewaterhouseCoopers，LLP）的保险高级助理，在那里她曾对投资管理客户进行审计。Clarke女士于2000年在福特汉姆大学（Fordham University）获得会计学学士学位，也是一名注册会计师。
Christine Clarke serves as our Chief Financial Officer. Ms. Clarke joined HealthCor in 2006 and has served as the Chief Financial Officer since 2007. Ms. Clarke’s responsibilities include accounting, operational, and human resources and she serves on the Executive, Valuation, Compliance, Expense, Best Execution, and Risk Committees. Prior to joining HealthCor, Ms. Clarke was the Controller at Narragansett Management, L.P. from 2004 to 2006. From 2000 until 2004 Ms. Clarke was an Assurance Senior Associate at PricewaterhouseCoopers, LLP where she conducted audits of investment management clients. Ms. Clarke received a B.S. in Accounting from Fordham University in 2000 and is also a Certified Public Accountant.- Christine Clarke是我们的首席财务官。Clarke女士于2006年加入Healthcor，自2007年起担任首席财务官。Clarke女士的职责包括会计，运营和人力资源，她在执行，评估，合规，费用，最佳执行和风险委员会任职。在加入Healthcor之前，Clarke女士从2004年到2006年担任Narragansett Management，L.P.的财务总监。从2000年到2004年，她曾担任普华永道会计师事务所（PricewaterhouseCoopers，LLP）的保险高级助理，在那里她曾对投资管理客户进行审计。Clarke女士于2000年在福特汉姆大学（Fordham University）获得会计学学士学位，也是一名注册会计师。
- Christine Clarke serves as our Chief Financial Officer. Ms. Clarke joined HealthCor in 2006 and has served as the Chief Financial Officer since 2007. Ms. Clarke’s responsibilities include accounting, operational, and human resources and she serves on the Executive, Valuation, Compliance, Expense, Best Execution, and Risk Committees. Prior to joining HealthCor, Ms. Clarke was the Controller at Narragansett Management, L.P. from 2004 to 2006. From 2000 until 2004 Ms. Clarke was an Assurance Senior Associate at PricewaterhouseCoopers, LLP where she conducted audits of investment management clients. Ms. Clarke received a B.S. in Accounting from Fordham University in 2000 and is also a Certified Public Accountant.
- George Petrocheilos
George Petrocheilos担任我们的总裁。Petrocheilos先生是Catalio的联合创始人和联合管理合伙人。在加入Catalio之前，Petrocheilos先生于2014年至2020年担任Camden Partners的普通合伙人，在那里他与Jacob Vogelstein博士一起创建并共同管理Nexus生命科学战略。Petrocheilos先生目前任职于几家私人生物技术公司的董事会，包括Mindx Corp.、Spiral Therapeutics、Windmil Therapeutics、SISU Global和LifeSprout Bio。Petrocheilos先生还担任肯尼迪·克雷格研究所（Kennedy Kreiger Institute）的董事会成员，这是一家约翰霍普金斯大学（Johns Hopkins）的医学附属机构。Petrocheilos先生于2013年毕业于约翰霍普金斯大学（Johns Hopkins University），获得金融经济学学士学位。
George Petrocheilos serves as our President. Mr. Petrocheilos is the Co-Founder and Co-Managing Partner of Catalio. Prior to Catalio, Mr. Petrocheilos was a General Partner at Camden Partners from 2014 through 2020 where he created and co-managed the Nexus life sciences strategy with Dr. Jacob Vogelstein. Mr. Petrocheilos currently serves on the Boards of several private biotechnology companies, including MindX Corp., Spiral Therapeutics, WindMIL Therapeutics, Sisu Global, and LifeSprout Bio. Mr. Petrocheilos also serves on the Board of Trustees of Kennedy Kreiger Institute, a Johns Hopkins Medicine affiliate. Mr. Petrocheilos graduated from Johns Hopkins University in 2013 with a B.A. in Financial Economics.- George Petrocheilos担任我们的总裁。Petrocheilos先生是Catalio的联合创始人和联合管理合伙人。在加入Catalio之前，Petrocheilos先生于2014年至2020年担任Camden Partners的普通合伙人，在那里他与Jacob Vogelstein博士一起创建并共同管理Nexus生命科学战略。Petrocheilos先生目前任职于几家私人生物技术公司的董事会，包括Mindx Corp.、Spiral Therapeutics、Windmil Therapeutics、SISU Global和LifeSprout Bio。Petrocheilos先生还担任肯尼迪·克雷格研究所（Kennedy Kreiger Institute）的董事会成员，这是一家约翰霍普金斯大学（Johns Hopkins）的医学附属机构。Petrocheilos先生于2013年毕业于约翰霍普金斯大学（Johns Hopkins University），获得金融经济学学士学位。
- George Petrocheilos serves as our President. Mr. Petrocheilos is the Co-Founder and Co-Managing Partner of Catalio. Prior to Catalio, Mr. Petrocheilos was a General Partner at Camden Partners from 2014 through 2020 where he created and co-managed the Nexus life sciences strategy with Dr. Jacob Vogelstein. Mr. Petrocheilos currently serves on the Boards of several private biotechnology companies, including MindX Corp., Spiral Therapeutics, WindMIL Therapeutics, Sisu Global, and LifeSprout Bio. Mr. Petrocheilos also serves on the Board of Trustees of Kennedy Kreiger Institute, a Johns Hopkins Medicine affiliate. Mr. Petrocheilos graduated from Johns Hopkins University in 2013 with a B.A. in Financial Economics.